Top

Published in:

01-09-2021 | Acute Lymphoblastic Leukemia | Review Article

Secondary Dysgammaglobulinemia in Children with Hematological Malignancies Treated with Targeted Therapies

Authors: Athanasios Tragiannidis, Andreas H. Groll

Published in: Pediatric Drugs | Issue 5/2021

Abstract

Targeted therapies have emerged as innovative treatments for patients whose disease does not respond to conventional chemotherapy, and their use has widely expanded in the field of pediatric hematologic malignancies in the last decade. While they carry the promise of improved disease control and survival and are currently investigated in first-line treatment protocols for patients with poor prognostic markers, they are associated with a considerable incidence of specific toxicities, including cytokine-release syndrome, neurotoxicity, hepatotoxicity, nephrotoxicity, cardiotoxicity, endocrine adverse events, and infectious complications. Iatrogenic or secondary dysgammaglobulinemia is a main consequence of targeted therapies using monoclonal antibodies and other antibody-derived treatments that target specific antigens on lymphoid cells (blinatumomab, inotuzumab ozogamicin, rituximab), chimeric antigen receptor T cells, tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib) and, to a lesser extent, checkpoint inhibitors (pembrolizumab, nivolumab). This review discusses the diagnosis and incidence of secondary or iatrogenic dysgammaglobulinemia in children treated with targeted therapies for leukemias and lymphomas, and options for monitoring and treatment.

Compagno N, Malipiero G, Cinetto F, Agostini C. Immunoglobulin replacement therapy in secondary hypogammaglobulinemia. Front Immunol. 2014;5:626.CrossRef

Patel SY, Carbone J, Jolles S. The expanding field of secondary antibody deficiency: causes, diagnosis, and management. Front Immunol. 2019;10:33.CrossRef

El-Bohy M, Poowuttikul P, Secord E. Humoral immune deficiencies of childhood. Pediatr Clin N Am. 2019;66:897–903.CrossRef

Gernez Y, Baker MG, Maglione PJ. Humoral immunodeficiencies: conferred risk of infections and benefits of immunoglobulin replacement therapy. Transfusion. 2018;58(Suppl 3):3056–64.CrossRef

Smith T, Cunningham-Rundles C. Primary B-cell immunodeficiencies. Hum Immunol. 2019;8:351–62.CrossRef

Srivastava S, Wood P. Secondary antibody deficiency—causes and approach to diagnosis. Clin Med. 2016;16:571–6.CrossRef

Jolles S, Chapel H, Litzman J. When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach. Clin Exp Immunol. 2017;188:333–41.CrossRef

Ragoonanan D, Khazal SJ, Mejia R, Ewing L, Durand JB, Bashoura L, et al. Case discussion and literature review: cancer immunotherapy, severe immune-related adverse events, multi-inflammatory syndrome, and severe acute respiratory syndrome coronavirus. Front Oncol. 2021;11:625707.CrossRef

Conde-Royo D, Juárez-Salcedo LM, Dalia S. Management of adverse effects of new monoclonal antibody treatments in acute lymphoblastic leukemia. Drugs Context. 2020. https://doi.org/10.7573/dic.2020-7-2.CrossRefPubMedPubMedCentral

10.

Curran E, O’Brien M. Role of blinatumomab, inotuzumab, and CAR T-cells: which to choose and how to sequence for patients with relapsed disease. Semin Hematol. 2020;57:157–63.CrossRef

11.

Pui CH. Precision medicine in acute lymphoblastic leukemia. Front Med. 2020;14:689–700.CrossRef

12.

Jasinski S, Deoseyes FA, Yametti GC, Pierro J, Raetz E, et al. Immunotherapy in pediatric B-cell acute lymphoblastic leukemia: advances and ongoing challenges. Paediatr Drugs. 2020;22:485–99.CrossRef

13.

Vora SB, Waghmare A, Englund JA, Qu P, Gardner RA, Hill JA. Infectious complications following CD19 chimeric antigen receptor T-cell therapy for children, adolescents, and young adults. Open Forum Infect Dis. 2020;7:121.CrossRef

14.

Ragoonanan D, Khazal SJ, Abdel-Azim H, McCall D, Cuglievan B, Tambaro FP, et al. Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nat Rev Clin Oncol. 2021. https://doi.org/10.1038/s41571-021-00474-4 (Epub ahead of print).CrossRefPubMed

15.

Los-Arcos I, Iacoboni G, Aguilar-Guisado M, Alsina-Manrique L, Díaz de Heredia C, Fortuny-Guasch C, et al. Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper. Infection. 2021;49:215–31.CrossRef

16.

Kyriakidis I, Vasileiou E, Rossig C, Roilides E, Groll AH, Tragiannidis A. Invasive fungal diseases in children with hematological malignancies treated with therapies that target cell surface antigens: monoclonal antibodies, immune checkpoint inhibitors and CAR T-cell therapies. J Fungi (Basel). 2021;7:186.CrossRef

17.

European Medicines Agency (EMEA). Blincyto. Summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf. Accessed on 8 Apr 2021.

18.

US Food & Drug Administration (FDA). Blincyto, summary of product characteristics. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125557s013lbl.pdf. Accessed on 19 Jun 2021.

19.

European Medicines Agency (EMEA). Besponsa. Summary of product characteristics. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761040s000lbl.pdf. Accessed on 8 Apr 2021.

20.

US Food & Drug Administration (FDA). Besponsa. Summary of product characteristics. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125557s013lbl.pdf. Accessed on 19 Jun 2021.

21.

European Medicines Agency (EMEA). MabThera. Summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf. Accessed on 8 Apr 2021

22.

US Food & Drug Administration (FDA). Mabthera. Summary of product characteristics. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103705s5367s5388lbl.pdf. Accessed on 19 Jun 2021.

23.

European Medicines Agency (EMEA). Darzalex. Summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/darzalex-epar-product-information_el.pdf. Accessed on 8 Apr 2021.

24.

US Food & Drug Administration (FDA). Darzalex summary of product characteristics. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761036s013lbl.pdf. Accessed on 19 Jun 2021.

25.

Jammal N, Chew S, Jabbour E, Kantarjian H. Antibody based therapy in relapsed acute lymphoblastic leukemia. Best Pract Res Clin Haematol. 2020;33: 101225. https://doi.org/10.1016/j.beha.2020.101225.CrossRefPubMed

26.

Chew S, Jammal N, Kantarjian H, Jabbour E. Monoclonal antibodies in frontline acute lymphoblastic leukemia. Best Pract Res Clin Haematol. 2020;33: 101226. https://doi.org/10.1016/j.beha.2020.101226.CrossRefPubMed

27.

Lanza F, Maffini E, Saraceni F, Massari E, Rondoni M, Daghia G, Olivieri A, Cerchione C, Martinelli G. New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia. Minerva Med. 2020;111:478–90. https://doi.org/10.23736/S0026-4806.20.07031-7.CrossRefPubMed

28.

Liu D, Zhao J, Song Y, Luo X, Yang T. Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia. J Hematol Oncol. 2019;12:15. https://doi.org/10.1186/s13045-019-0703-z.CrossRefPubMedPubMedCentral

29.

Jain T, Litzow MR. Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia. Ther Adv Hematol. 2020;11:2040620719899897. https://doi.org/10.1177/2040620719899897.CrossRefPubMedPubMedCentral

30.

Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121:5154–7. https://doi.org/10.1182/blood-2013-02-485623.CrossRefPubMedPubMedCentral

31.

Stein AS, Schiller G, Benjamin R, Jia C, Zhang A, Zhu M, Zimmerman Z, et al. Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors. Ann Hematol. 2019;98:159–67. https://doi.org/10.1007/s00277-018-3497-0.CrossRefPubMed

32.

Zugmaier G, Topp MS, Alekar S, Viardot A, Horst HA, Neumann S, et al. Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer J. 2014;4:244. https://doi.org/10.1038/bcj.2014.64.PMID:25192414;PMCID:PMC4183773.CrossRefPubMedPubMedCentral

33.

Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836–47. https://doi.org/10.1056/NEJMoa1609783.CrossRefPubMedPubMedCentral

34.

Topp MS, Kufer P, Gökbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29:2493–8. https://doi.org/10.1200/JCO.2010.32.7270.CrossRefPubMed

35.

Queudeville M, Schlegel P, Heinz AT, Lenz T, Döring M, Holzer U, et al. Blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Eur J Haematol. 2021;106:473–83. https://doi.org/10.1111/ejh.13569.CrossRefPubMed

36.

Mikhailova E, Semchenkova A, Illarionova O, Kashpor S, Brilliantova V, Zakharova E, et al. Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease. Br J Haematol. 2021;193:602–12. https://doi.org/10.1111/bjh.17382.CrossRefPubMed

37.

Sutton R, Pozza LD, Khaw SL, Fraser C, Revesz T, Chamberlain J, et al. Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab. Pediatr Blood Cancer. 2021;68: e28922. https://doi.org/10.1002/pbc.28922.CrossRefPubMed

38.

Locatelli F, Zugmaier G, Mergen N, Bader P, Jeha S, Schlegel PG, et al. Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study. Blood Cancer J. 2020;10(7):77. https://doi.org/10.1038/s41408-020-00342-x.Erratum.In:BloodCancerJ.2021;11:28.CrossRefPubMedPubMedCentral

39.

Brown PA, Ji L, Xu X, Devidas M, Hogan LE, Borowitz MJ, et al. Effect of Postreinduction Therapy Consolidation With blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of b-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325(9):833–42. https://doi.org/10.1001/jama.2021.0669.CrossRefPubMedPubMedCentral

40.

Locatelli F, Zugmaier G, Rizzari C, Morris JD, Gruhn B, Klingebiel T, et al. Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse b-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325:843–54. https://doi.org/10.1001/jama.2021.0987.CrossRefPubMedPubMedCentral

41.

Jasinski S, De Los Reyes FA, Yametti GC, Pierro J, Raetz E, Carroll WL. Immunotherapy in pediatric b-cell acute lymphoblastic leukemia: advances and ongoing challenges. Paediatr Drugs. 2020;22:485–99. https://doi.org/10.1007/s40272-020-00413-3.CrossRefPubMed

42.

Drgona L, Gudiol C, Lanini S, Salzberger B, Ippolito G, Mikulska M. ESCMID study group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). Clin Microbiol Infect. 2018;24(Suppl 2):S83–94. https://doi.org/10.1016/j.cmi.2018.03.022.CrossRefPubMed

43.

Fayad L, Offner F, Smith MR, Verhoef G, Johnson P, Kaufman JL, et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol. 2013;31:573–83. https://doi.org/10.1200/JCO.2012.42.7211.CrossRefPubMedPubMedCentral

44.

Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375:740–53. https://doi.org/10.1056/NEJMoa1509277.CrossRefPubMedPubMedCentral

45.

Zian Z, Berry SPD, Bahmaie N, Ghotbi D, Kashif A, Madkaikar M, et al. The clinical efficacy of Rituximab administration in autoimmunity disorders, primary immunodeficiency diseases and malignancies. Int Immunopharmacol. 2021;95: 107565. https://doi.org/10.1016/j.intimp.2021.107565.CrossRefPubMed

46.

Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs. 2003;63:803–43. https://doi.org/10.2165/00003495-200363080-00005.CrossRefPubMed

47.

Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol. 2008;20:444–9. https://doi.org/10.1016/jI.2008.05.011.CrossRefPubMedPubMedCentral

48.

Cang S, Mukhi N, Wang K, Liu D. Novel CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol. 2012;5:64. https://doi.org/10.1186/1756-8722-5-64.CrossRefPubMedPubMedCentral

49.

Mahmoudi H, Tavakolpour S, Balighi K, Farid AS, Nili A, Jan D, Daneshpazhooh M. Rituximab in practice: clinical evaluation of patients with pemphigus after rituximab administration. Dermatol Ther. 2021;34: e14633. https://doi.org/10.1111/dth.14633.CrossRefPubMed

50.

Samson M, Fraser W, Lebowitz D. Treatments for primary immune thrombocytopenia: a review. Cureus. 2019;11: e5849. https://doi.org/10.7759/cureus.5849.CrossRefPubMedPubMedCentral

51.

Dou X, Yang R. Current and emerging treatments for immune thrombocytopenia. Expert Rev Hematol. 2019;12:723–32. https://doi.org/10.1080/17474086.2019.1636644.CrossRefPubMed

52.

Murakhovskaya I. Rituximab use in warm and cold autoimmune hemolytic anemia. J Clin Med. 2020;9:4034. https://doi.org/10.3390/jcm9124034.CrossRefPubMedCentral

53.

Zaja F, Iacona I, Masolini P, Russo D, Sperotto A, Prosdocimo S, et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica. 2002;87:189–95.PubMed

54.

Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk. 2013;13:106–11. https://doi.org/10.1016/j.clml.2012.11.011.CrossRefPubMed

55.

Masjosthusmann K, Ehlert K, Eing BR, Roth J, Koehler G, Juergens H, Fruehwald M, Groll AH. Delay in B-lymphocyte recovery and function following rituximab for EBV-associated lymphoproliferative disease early post-allogeneic hematopoietic SCT. Bone Marrow Transplant. 2009;43:679–84. https://doi.org/10.1038/bmt.2008.385.CrossRefPubMed

56.

Chiou FK, Beath SV, Patel M, Gupte GL. Hypogammaglobulinemia and bacterial infections following pediatric post-transplant lymphoproliferative disorder in the rituximab era. Pediatr Transplant. 2019;23: e13519. https://doi.org/10.1111/petr.13519.CrossRefPubMed

57.

Maschan A, Myakova N, Aleinikova O, Abugova Y, Ponomareva N, Belogurova M, et al. Rituximab and reduced-intensity chemotherapy in children and adolescents with mature B-cell lymphoma: interim results for 231 patients enrolled in the second Russian-Belorussian multicentre study B-NHL-2010M. Br J Haematol. 2019;186:477–83. https://doi.org/10.1111/bjh.15944.CrossRefPubMed

58.

Worch J, Makarova O, Burkhardt B. Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults? Cancers (Basel). 2015. https://doi.org/10.3390/cancers7010305.CrossRef

59.

Meinhardt A, Schadwill S, Zimmermann M, Gruhn B, Behnisch W, Becker M, et al. Serum immunoglobulin levels in children and adolescents after B-NHL BFM chemotherapy with and without one dose of rituximab. 2009;3:Abstract 036

60.

Samochatova EV, Maschan AA, Shelikhova LN, Myakova NV, Belogurova MB, et al. Therapy of advanced-stage mature B-cell lymphoma and leukemia in children and adolescents with rituximab and reduced intensity induction chemotherapy (B-NHL 2004M protocol): the results of a multicenter study. J Pediatr Hematol Oncol. 2014;36:395–401. https://doi.org/10.1097/MPH.0b013e31829d4900.CrossRefPubMed

61.

Srinivasan S, Roy Moulik N, Kc A, Narula G, Sankaran H, Prasad M, Dhamne C, Cheriyalinkal Parambil B, Shah S, Shet T, Sridhar E, Gujral S, Banavali S. Increased toxicities in children with Burkitt lymphoma treated with rituximab: Experience from a tertiary cancer center in India. Pediatr Blood Cancer. 2020;67: e28682. https://doi.org/10.1002/pbc.28682.CrossRefPubMed

62.

Minard-Colin V, Aupérin A, Pillon M, Burke GAA, Barkauskas DA, Wheatley K, et al. European intergroup for childhood non-hodgkin lymphoma children’s oncology group rituximab for high-risk mature B-cell non-hodgkin’s lymphoma in children. N Engl J Med. 2020;382:2207–19. https://doi.org/10.1056/NEJMoa1915315.CrossRefPubMedPubMedCentral

63.

European Medicines Agency (EMEA). Kymriah. Summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/kymriah-epar-product-information_en.pdf. Accessed on 8 Apr 2021.

64.

European Medicines Agency (EMEA). Tecartus. Summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/tecartus-epar-product-information_en.pdf. Accessed on 8 Apr 2021

65.

US Food & Drug Administration (FDA). Kymriah. Summary of product characteristics. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/kymriah-tisagenlecleucel. Accessed on 19 Jun 2021.

66.

Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509–18. https://doi.org/10.1056/NEJMoa1215134.CrossRefPubMedPubMedCentral

67.

Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–17. https://doi.org/10.1056/NEJMoa1407222.CrossRefPubMedPubMedCentral

68.

Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–48. https://doi.org/10.1056/NEJMoa1709866.CrossRefPubMedPubMedCentral

69.

Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24:731–8. https://doi.org/10.1038/s41591-018-0041-7.CrossRefPubMedPubMedCentral

70.

71.

Deyà-Martínez A, Alonso-Saladrigues A, García AP, Faura A, Torrebadell M, Vlagea A, et al. Kinetics of humoral deficiency in CART19-treated children and young adults with acute lymphoblastic leukaemia. Bone Marrow Transplant. 2021;56:376–86. https://doi.org/10.1038/s41409-020-01027-6.CrossRefPubMed

72.

Cordeiro A, Bezerra ED, Hirayama AV, Hill JA, Wu QV, Voutsinas J, et al. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells. Biol Blood Marrow Transplant. 2020;26:26–33. https://doi.org/10.1016/j.bbmt.2019.08.003.CrossRefPubMed

73.

Metzger ML, Mauz-Körholz C. Epidemiology, outcome, targeted agents and immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin lymphoma. Br J Haematol. 2019;185:1142–57. https://doi.org/10.1111/bjh.15789.CrossRefPubMed

74.

Dumaswala K, Mehta A. Novel agents for the treatment of Hodgkin lymphoma. Expert Rev Hematol. 2015;8:659–67. https://doi.org/10.1586/17474086.2015.1081562.P.CrossRefPubMed

75.

Castagna L, Santoro A, Carlo-Stella C. Salvage therapy for Hodgkin’s lymphoma: a review of current regimens and outcomes. J Blood Med. 2020;27(11):389–403. https://doi.org/10.2147/JBM.S250581.CrossRef

76.

European Medicines Agency (EMEA). Keytruda. Summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Accessed on 8 Apr 2021.

77.

US Food & Drug Administration (FDA). Keytruda, Summary of product characteristics. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125514s096lbl.pdf. Accessed on 19 Jun 2021.

78.

Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, et al. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial. Lancet Oncol. 2020;21:121–33. https://doi.org/10.1016/S1470-2045(19)30671-0.CrossRefPubMed

79.

European Medicines Agency (EMEA). Opdivo. Summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Accessed on 8 Apr 2021.

80.

MarjaŃska A, Drogosiewicz M, Dembowska-BagiŃska B, PawiŃska-Wąsikowska K, Balwierz W, Bobeff K, et al. Nivolumab for the treatment of advanced pediatric malignancies. Anticancer Res. 2020;40:7095–100. https://doi.org/10.21873/anticanres.14738.CrossRefPubMed

81.

Davis KL, Fox E, Merchant MS, Reid JM, Kudgus RA, Liu X, et al. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial. Lancet Oncol. 2020;21:541–50.CrossRef

82.

European Medicines Agency (EMEA). Glivec. Summary of product characteristics. https://www.ema.europa.eu/en/medicines/human/EPAR/glivec. Accessed on 8 Apr 2021.

83.

US Food & Drug Administration (FDA). Glivec, Summary of product characteristics. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf. Accessed on 19 Jun 2021.

84.

European Medicines Agency (EMEA). Sprycel. Summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf. Accessed on 8 Apr 2021.

85.

US Food & Drug Administration (FDA). Sprycel, summary of product characteristics. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021986s020lbl.pdf. Accessed on 19 Jun 2021.

86.

European Medicines Agency (EMEA). Tasigna. Summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/tasigna-epar-product-information_en.pdf. Accessed on 8 Apr 2021.

87.

US Food & Drug Administration (FDA). Tasigna, Summary of product characteristics. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022068s004s005lbl.pdf. Accessed on 19 Jun 2021.

88.

Drozdov D, Bonaventure A, Nakata K, Suttorp M, Belot A. Temporal trends in the proportion of “cure” in children, adolescents, and young adults diagnosed with chronic myeloid leukemia in England: a population-based study. Pediatr Blood Cancer. 2018;65:e27422. https://doi.org/10.1002/pbc.27422.CrossRefPubMed

89.

Chen M, Zhu Y, Lin Y, Tengwang T, Zhang L. Use of tyrosine kinase inhibitors for paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia: a systematic review and meta-analysis. BMJ Open. 2021;11:e042814. https://doi.org/10.1136/bmjopen-2020-042814.CrossRefPubMedPubMedCentral

90.

Santachiara R, Maffei R, Martinelli S, Arcari A, Piacentini F, Trabacchi E, et al. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor. Haematologica. 2008;93:1252–5. https://doi.org/10.3324/haematol.12642.CrossRefPubMed

91.

Totadri S, Thipparapu S, Aggarwal R, Sharma M, Naseem S, Jain R, et al. Imatinib-induced hypogammaglobulinemia in children and adolescents with chronic myeloid leukemia. Pediatr Hematol Oncol. 2020;37:539–44. https://doi.org/10.1080/08880018.2020.1759739.CrossRefPubMed

92.

Ota S, Matsukawa T, Yamamoto S, Ito S, Shindo M, Sato K, et al. Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia. Eur J Haematol. 2018;101:95–105. https://doi.org/10.1111/ejh.13081.CrossRefPubMed

93.

Biondi A, Schrappe M, De Lorenzo P, Castor A, Lucchini G, Gandemer V, et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol. 2012;13:936–45. https://doi.org/10.1016/S1470-2045(12)70377-7.CrossRefPubMedPubMedCentral

94.

Fachi MM, Tonin FS, Leonart LP, Rotta I, Fernandez-Llimos F, Pontarolo R. Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: a network meta-analysis. Br J Clin Pharmacol. 2019;85:2280–91. https://doi.org/10.1111/bcp.13933.CrossRefPubMedPubMedCentral

95.

Ando T, Kojima K, Isoda H, Eguchi Y, Honda T, Ishigami M, et al. Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia. Int J Hematol. 2015;102:379–82. https://doi.org/10.1007/s12185-015-1788-y.CrossRefPubMed

96.

Jahnz-RÓŻyk K, WiĘsik-Szewczyk E, RoliŃski J, Siedlar M, Jędrzejczak W, Sydor W, et al. Secondary immunodeficiencies with predominant antibody deficiency: multidisciplinary perspectives of Polish experts. Cent Eur J Immunol. 2020;45:334–41. https://doi.org/10.5114/ceji.2020.101265.CrossRefPubMedPubMedCentral

97.

Eichhorst B, Robak T, Montserrat E, et al. ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v78-84.CrossRef

98.

Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745–60.CrossRef

99.

Snowden JA, Ahmedzai SH, Ashcroft J, et al. Guidelines for supportive care in multiple myeloma 2011. Br J Hematol. 2011;154:76–103.CrossRef

100.

Ahn H, Shea B, Hutton B, et al. Effectiveness of immunoglobulin prophylaxis in reducing clinical complications of hematopoietic stem cell transplantation: a systematic review and meta-analysis. Transfusion. 2018;58:2437–52.CrossRef

101.

Sánchez-Ramón S, Dhalla F, Chapel H. Challenges in the role of gammaglobulin replacement therapy and vaccination strategies for hematological malignancy. Front Immunol. 2016;7:317. https://doi.org/10.3389/fimmu.2016.00317.CrossRefPubMedPubMedCentral

Title: Secondary Dysgammaglobulinemia in Children with Hematological Malignancies Treated with Targeted Therapies
Authors: Athanasios Tragiannidis
Andreas H. Groll
Publication date: 01-09-2021
Publisher: Springer International Publishing
Keywords: Acute Lymphoblastic Leukemia
Chronic Myeloid Leukemia
Rituximab
Tyrosine Kinase Inhibitors
Targeted Therapy
Tyrosine Kinase Inhibitors
Dasatinib
Imatinib
Nilotinib
Blinatumomab
Inotuzumab Ozogamicin
Rituximab
Published in: Pediatric Drugs / Issue 5/2021
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI: https://doi.org/10.1007/s40272-021-00461-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Secondary Dysgammaglobulinemia in Children with Hematological Malignancies Treated with Targeted Therapies

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2021

Targeted Therapy in Pediatric AML: An Evolving Landscape

Laboratory Safety of Dupilumab in Patients Aged 6–11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial

Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria

Pharmacokinetics of Ceftazidime in Children and Adolescents with Obesity

Managing Patient Pressure to Prescribe Antibiotics in the Clinic

Pediatric Urologic Surgery: Reducing Opioid Use